Silence Therapeutics (SLN) Total Non-Current Liabilities: 2019-2024
Historic Total Non-Current Liabilities for Silence Therapeutics (SLN) over the last 4 years, with Sep 2024 value amounting to -$75.3 million.
- Silence Therapeutics' Total Non-Current Liabilities rose 0.80% to -$75.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$75.3 million, marking a year-over-year increase of 0.80%. This contributed to the annual value of $73.4 million for FY2023, which is 6.59% down from last year.
- According to the latest figures from Q3 2024, Silence Therapeutics' Total Non-Current Liabilities is -$75.3 million, which was down 2.53% from -$73.4 million recorded in Q2 2024.
- Silence Therapeutics' Total Non-Current Liabilities' 5-year high stood at $97.7 million during Q4 2021, with a 5-year trough of -$90.0 million in Q1 2022.
- In the last 3 years, Silence Therapeutics' Total Non-Current Liabilities had a median value of -$75.3 million in 2024 and averaged -$49.9 million.
- As far as peak fluctuations go, Silence Therapeutics' Total Non-Current Liabilities spiked by 239.82% in 2020, and later declined by 23.81% in 2022.
- Silence Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $67.8 million in 2020, then spiked by 44.17% to $97.7 million in 2021, then declined by 23.81% to $74.5 million in 2022, then dropped by 1.65% to $73.2 million in 2023, then climbed by 0.80% to -$75.3 million in 2024.
- Its last three reported values are -$75.3 million in Q3 2024, -$73.4 million for Q2 2024, and -$71.4 million during Q1 2024.